PhillyTablet Inquirer Daily News
Mobile
Home Delivery
philly.com
email
font size
comments
0
options
 
Friday, October 16, 2009

FDA approves GlaxoSmithKline's Cervarix vaccine

GlaxoSmithKline P.L.C. this morning said the U.S. Food and Drug Administration approved its Cervarix cervical cancer vaccine.

The pharmaceutical company, which has major operations in the Philadelphia area, said it will begin marketing and selling the vaccine in late 2009.

The decision was expected after an FDA advisory panel recommended approval in September. And it means that Merck & Co. Inc. now has some competition for its Gardasil vaccine, which also protects against two types of human papillomavirus. Merck's Gardasil had 2008 sales of $1.4 billion.

To read more about Cervarix, here's a link to a September story by the Inquirer's Marie McCullough.
Posted by Mike Armstrong @ 11:24 AM  Permalink | File Under: Pharma, Biotech | Post a comment
Comments   


0 comments
About Mike Armstrong
Mike Armstrong, a business editor and writer for nearly two decades, is the Inquirer's business columnist and PhillyInc blog editor. Contact Mike via e-mail or at 215-854-2980
Advertise Here